BioSpace News Archive

Additional Analysis Shows Potential of Biktarvy to Be an Important Treatment Option for People Living With HIV Who are Virologically Suppressed and Have End Stage Renal Disease Requiring Hemodialysis

Medly partners with EmblemHealth and the New York City Housing Authority to provide underserved communities in the Brooklyn area access to the influenza vaccination

Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology

Established in 2015, Florida privately-owned research and lab facility continues to be integral part of the fight against COVID-19 in our communities

ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is delivering process systems to Ology Bioservices Inc. (Ology Bio) to support their production of critical vaccines and therapeutics for COVID-19. ABEC is providing these systems to Ology Bios

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today the successful outcome of its October 14, 2020 meeting with FDA. The purpose of the meeting was to finalize the protocol (procedure) for its n

Robotic technology and automation currently assist healthcare professionals with patient care, medical research, surgical procedures, and more. The popularity of robotic technology appears to be on the rise with continued growth into the future, which may prove to be beneficial for healthcare institutions looking to promote their services to new consumers during the final quarter of the financial year.

Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol ® Cyclo™ for treatment of Niemann-Pick Disease Type C

Clenova has further expanded its production capacity to meet the high demand for hand sanitizers and hand soaps. They now have five full production lines dedicated to making these essential hand cleaning products.

Reference is made to the stock exchange announcement by Nordic Nanovector ASA (the “Company”) on 23 and 30 September 2020 where the Company announced the successful completion of a private placement raising gross proceeds of approximately NOK 231 million (the “Private Placement”) and that the board of directors would consider to